Analyst consensus rating

CorMedix Analyst Rating: Buy

Direct answer

CorMedix's consensus rating is Buy.

5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.80.
Forecast evidence checked November 17, 2026.

Get free CorMedix email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$4.82
Average price target
$13.80
High price target
$17.00
Low price target
$12.00
Low target gap
+149%
Target upside
+186.3%
High target gap
+252.7%
Target range width
103.7%
Consensus rating
Buy
Analysts
5
Evidence date
November 17, 2026
Valid through
November 24, 2026

Read the frequently asked questions.

What is the analyst consensus rating for CorMedix?

CorMedix has a verified Buy consensus. The same dataset has an average price target of $13.80.

How far are CorMedix's low and high targets from the recorded price?

The low target implies +149%, while the high target implies +252.7%.

How many analysts are included in CorMedix's consensus?

The verified consensus includes 5 analysts.

How is CorMedix's target upside or downside calculated?

The average target of $13.80 is divided by the recorded price of $4.82, then one is subtracted to produce +186.3%. This does not guarantee a future return.

When was CorMedix's analyst forecast verified?

The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.